Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Transparency Market Research | PRODUCT CODE: 1110367

Cover Image

PUBLISHER: Transparency Market Research | PRODUCT CODE: 1110367

Nonalcoholic Steatohepatitis Therapeutics Market (Drug Type: Obeticholic Acid (OCA), Aramchol (Arachidyl Amido Cholanoic Acid), Saroglitazar, and Elafibranor) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 5795
PDF (Multi-user License)
USD 8795
PDF (Corporate License)
USD 11795

Add to Cart

The report provides revenue of the global nonalcoholic steatohepatitis therapeutics market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global nonalcoholic steatohepatitis therapeutics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the nonalcoholic steatohepatitis therapeutics market.

The report delves into the competitive landscape of the global nonalcoholic steatohepatitis therapeutics market. Key players operating in the global nonalcoholic steatohepatitis therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global nonalcoholic steatohepatitis therapeutics market profiled in this report.

Product Code: TMRGL7691

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Nonalcoholic Steatohepatitis Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Drug Type Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Key Product/ Brand Analysis
  • 5.2. Key industry events (mergers, acquisitions, product launches etc.)
  • 5.3. Technological Advancements
  • 5.4. Regulatory Scenario, by Region/ Globally
  • 5.5. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)

6. Global Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug Type, 2017-2031
    • 6.3.1. Obeticholic Acid (OCA)
    • 6.3.2. Aramchol (arachidyl amido cholanoic acid)
    • 6.3.3. Saroglitazar
    • 6.3.4. Elafibranor
  • 6.4. Market Attractiveness By Drug Type

7. Global Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast, by Region

  • 7.1. Key Findings
  • 7.2. Market Value Forecast, by Region
    • 7.2.1. North America
    • 7.2.2. Europe
    • 7.2.3. Asia Pacific
    • 7.2.4. Latin America
    • 7.2.5. Middle East & Africa
  • 7.3. Market Attractiveness Analysis, by Region

8. North America Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast

  • 8.1. Introduction
    • 8.1.1. Key Findings
  • 8.2. Market Value Forecast, by Drug Type, 2017-2031
    • 8.2.1. Obeticholic Acid (OCA)
    • 8.2.2. Aramchol (arachidyl amido cholanoic acid)
    • 8.2.3. Saroglitazar
    • 8.2.4. Elafibranor
  • 8.3. Market Value Forecast, by Country, 2017-2031
    • 8.3.1. U.S.
    • 8.3.2. Canada
  • 8.4. Market Attractiveness Analysis
    • 8.4.1. By Drug Type
    • 8.4.2. By Country

9. Europe Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Drug Type, 2017-2031
    • 9.2.1. Obeticholic Acid (OCA)
    • 9.2.2. Aramchol (arachidyl amido cholanoic acid)
    • 9.2.3. Saroglitazar
    • 9.2.4. Elafibranor
  • 9.3. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 9.3.1. Germany
    • 9.3.2. U.K.
    • 9.3.3. France
    • 9.3.4. Spain
    • 9.3.5. Italy
    • 9.3.6. Rest of Europe
  • 9.4. Market Attractiveness Analysis
    • 9.4.1. By Drug Type
    • 9.4.2. By Country/Sub-region

10. Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Type, 2017-2031
    • 10.2.1. Obeticholic Acid (OCA)
    • 10.2.2. Aramchol (arachidyl amido cholanoic acid)
    • 10.2.3. Saroglitazar
    • 10.2.4. Elafibranor
  • 10.3. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia & New Zealand
    • 10.3.5. Rest of Asia Pacific
  • 10.4. Market Attractiveness Analysis
    • 10.4.1. By Drug Type
    • 10.4.2. By Country/Sub-region

11. Latin America Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Type, 2017-2031
    • 11.2.1. Obeticholic Acid (OCA)
    • 11.2.2. Aramchol (arachidyl amido cholanoic acid)
    • 11.2.3. Saroglitazar
    • 11.2.4. Elafibranor
  • 11.3. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.3.1. Brazil
    • 11.3.2. Mexico
    • 11.3.3. Rest of Latin America
  • 11.4. Market Attractiveness Analysis
    • 11.4.1. By Drug Type
    • 11.4.2. By Country/Sub-region

12. Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Type, 2017-2031
    • 12.2.1. Obeticholic Acid (OCA)
    • 12.2.2. Aramchol (arachidyl amido cholanoic acid)
    • 12.2.3. Saroglitazar
    • 12.2.4. Elafibranor
  • 12.3. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.3.1. GCC Countries
    • 12.3.2. South Africa
    • 12.3.3. Rest of Middle East & Africa
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Drug Type
    • 12.4.2. By Country/Sub-region

13. Competition Landscape

  • 13.1. Market Player - Competition Matrix (by tier and size of companies)
  • 13.2. Market Share Analysis By Company (2021)
  • 13.3. Company Profiles
    • 13.3.1. F. Hoffmann-La Roche
      • 13.3.1.1. Company Overview (HQ, Business Segments, Employee)
      • 13.3.1.2. Product Portfolio
      • 13.3.1.3. SWOT Analysis
      • 13.3.1.4. Strategic Overview
    • 13.3.2. Siemens Healthineers AG.
      • 13.3.2.1. Company Overview (HQ, Business Segments, Employee)
      • 13.3.2.2. Product Portfolio
      • 13.3.2.3. SWOT Analysis
      • 13.3.2.4. Strategic Overview
    • 13.3.3. Thermo Fisher Scientific
      • 13.3.3.1. Company Overview (HQ, Business Segments, Employee)
      • 13.3.3.2. Product Portfolio
      • 13.3.3.3. SWOT Analysis
      • 13.3.3.4. Strategic Overview
    • 13.3.4. Danaher Corporation
      • 13.3.4.1. Company Overview (HQ, Business Segments, Employee)
      • 13.3.4.2. Product Portfolio
      • 13.3.4.3. SWOT Analysis
      • 13.3.4.4. Strategic Overview
    • 13.3.5. Bio-Rad Laboratories
      • 13.3.5.1. Company Overview (HQ, Business Segments, Employee)
      • 13.3.5.2. Product Portfolio
      • 13.3.5.3. SWOT Analysis
      • 13.3.5.4. Strategic Overview
    • 13.3.6. Abbott Laboratories
      • 13.3.6.1. Company Overview (HQ, Business Segments, Employee)
      • 13.3.6.2. Product Portfolio
      • 13.3.6.3. SWOT Analysis
      • 13.3.6.4. Strategic Overview
    • 13.3.7. Alpco
      • 13.3.7.1. Company Overview (HQ, Business Segments, Employee)
      • 13.3.7.2. Product Portfolio
      • 13.3.7.3. SWOT Analysis
      • 13.3.7.4. Strategic Overview
    • 13.3.8. Beckman Coulter Inc.
      • 13.3.8.1. Company Overview (HQ, Business Segments, Employee)
      • 13.3.8.2. Product Portfolio
      • 13.3.8.3. SWOT Analysis
      • 13.3.8.4. Strategic Overview
    • 13.3.9. Chromsystems Instrume
      • 13.3.9.1. Company Overview (HQ, Business Segments, Employee)
      • 13.3.9.2. Product Portfolio
      • 13.3.9.3. SWOT Analysis
      • 13.3.9.4. Strategic Overview
    • 13.3.10. Pharmaceutical Drug Type Development LLC
      • 13.3.10.1. Company Overview (HQ, Business Segments, Employee)
      • 13.3.10.2. Product Portfolio
      • 13.3.10.3. SWOT Analysis
      • 13.3.10.4. Strategic Overview
    • 13.3.11. Randox Laboratories Ltd.
      • 13.3.11.1. Company Overview (HQ, Business Segments, Employee)
      • 13.3.11.2. Product Portfolio
      • 13.3.11.3. SWOT Analysis
      • 13.3.11.4. Strategic Overview
    • 13.3.12. Other prominent players
      • 13.3.12.1. Company Overview (HQ, Business Segments, Employee)
      • 13.3.12.2. Product Portfolio
      • 13.3.12.3. SWOT Analysis
      • 13.3.12.4. Strategic Overview
Product Code: TMRGL7691

List of Tables

  • Table 01: Global Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 02: Global Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Region, 2017-2031
  • Table 03: North America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country, 2017-2031
  • Table 04: North America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
  • Table 05: Europe Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031
  • Table 06: Europe Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
  • Table 07: Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031
  • Table 08: Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
  • Table 09: Latin America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Latin America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
  • Table 11: Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031
  • Table 12: Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

List of Figures

  • Figure 01: Global Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Figure 02: Global Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Region, 2017-2031
  • Figure 03: North America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country, 2017-2031
  • Figure 04: North America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
  • Figure 05: Europe Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031
  • Figure 06: Europe Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
  • Figure 07: Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031
  • Figure 08: Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
  • Figure 09: Latin America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031
  • Figure 10: Latin America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
  • Figure 11: Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031
  • Figure 12: Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
  • Figure 13: Global Nonalcoholic Steatohepatitis Therapeutics Market Share Analysis, by Company (2021)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!